The Valley Desk

NCT05579366 · Interventional trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Breast Adenocarcinoma, Cervical Cancer, Endometrial Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Fallopian Tube Cancer, High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Mesothelioma, Non-small Cell Lung Cancer, Platinum Sensitive Ovarian Cancer (PSOC), Platinum-resistant Ovarian Cancer (PROC), Primary Peritoneal Carcinoma, Primary Refractory Ovarian Cancer, Triple Negative Breast Cancer, Uterine Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov